Industry Updates for the Psychedelics World

Psychedelics News

Industry

22 Sep 2023

Cybin Completes Phase 2 Enrollment of CYB003 for Major Depressive Disorder

Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder....

By Microdose NewsDesk

Industry

21 Sep 2023

Seelos Therapeutics Announces Results from Phase II Depression Trial

Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide....

By Microdose NewsDesk

Industry

20 Sep 2023

Numinus Closes Bioscience Lab and Consolidates Clinics

Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations....

By Microdose NewsDesk

Industry

14 Sep 2023

MAPS Publishes Results of Successful Phase 3 Trial

In big industry news, MAPS has published the second part of its long-awaited Phase 3 trial of MDMA-assisted therapy for PTSD....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

12 Sep 2023

MindMed Completes Dosing of Phase 2b Trial

MindMed has completed dosing of its main Phase 2b clinical trial. The study — investigating LSD for Generalized Anxiety Disorder (GAD) — has dosed 198 participants across 20 clinical sites....

By Microdose NewsDesk

Industry

11 Sep 2023

PurMinds Appoints Leading Drug Designer to Scientific Advisory Board

Dr. Kozikowski is a leader in medicinal chemistry designing Novel Chemical Entities (NCEs) for oncology and neuroscience....

By Microdose NewsDesk

Industry

8 Sep 2023

Microdose Partners with Concordia for 2023 Annual Summit in New York City

Microdose is partnering with Concordia for the 2023 Concordia Annual Summit, taking place September 18-20 in New York City....

By Microdose NewsDesk

Industry

7 Sep 2023

Awakn Life Sciences Submits Clinical Trial Application for Phase 3 Trial

Awakn Life Sciences has submitted a Clinical Trial Application for a phase III trial for its lead program for the treatment of Severe Alcohol Use Disorder....

By Microdose NewsDesk

Industry

5 Sep 2023

Cybin Granted U.S. Patent for 5-MeO-DMT

The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine (5-MeO-DMT) analogs....

By Microdose NewsDesk

Follow us on social

Latest News

Reading the Brain’s Response: Enveric’s EB-003 Takes a Step Toward Human Testing

The Cost of Waiting: What Compass’s Depression Survey Means for Psychedelic Medicine

Beyond the Psychedelic Experience: Enveric Biosciences Takes Another Step Toward a New Generation of Mental Health Treatments

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result